An Exploratory, Open-Lael Study to Assess the Effects of AZD2171 on Tumors and Biomarkers in Patients With Previously Untreated or Recurrent Non-small Cell Lung Cancer (NSCLC) or Patients With Metastatic or Recurrent Head and Neck Cancer (HNC)

Inclusion Criteria:

- Histologically or cytologically confirmed head and neck cancer (HNC) or unresectable
stage IIIb or IV non-small cell lung cancer (NSCLC)

- At least one lesion able to be used for tumor biopsy and to be measured by FDG-PET
Scan

- Considered suitable for treatment of NSCLC with no prior biological or immunological
therapy for disease

- Or considered suitable for treatment for metastatic or recurrent HNC with no prior
biological or immunological therapy for disease

Exclusion Criteria:

- NSCLC: Have received more than 2 previous chemotherapy regimens or have received the
last chemotherapy or radiotherapy within 28 days of first dose of AZD2171

- HNC: Previous chemotherapy or radiotherapy if received 28 days of first dose of
AZD2171

- Untreatable, unstable brain or meningeal metastases.

- Abnormal liver and kidney blood chemistries

- History of poorly controlled hypertension with resting blood pressure of >150/100

- Recent (< 14 days) major surgery or a surgical incision not fully healed

- Diabetes patients with type I insulin dependent diabetes or poorly controlled type II

- Significant hemorrhage or hemoptysis

- Presence of necrotic/hemorrhagic tumor or metastases